Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony‑stimulating factor presented as an injectable solution for intravenous and subcutaneous administration. It is used to reduce the duration of neutropenia in patients receiving chemotherapy, to support neutrophil recovery after bone‑marrow transplantation, to treat severe chronic neutropenia, and to mobilize peripheral blood stem cells for collection.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, and adheres to EU quality standards.

Neupogen (filgrastim) is a granulocyte colony‑stimulating factor used to manage neutropenia in several clinical settings.

- Chemotherapy‑induced neutropenia: reduces the duration and severity of neutropenia in patients receiving cytotoxic chemotherapy. - Bone marrow transplantation–associated neutropenia: promotes neutrophil recovery following hematopoietic stem cell transplant. - Severe chronic neutropenia: increases neutrophil counts in patients with congenital or idiopathic chronic neutropenia. - Peripheral blood stem cell mobilization: enhances mobilization of hematopoietic stem cells for collection prior to autologous transplantation.

Filgrastim may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Bone pain: mild to moderate discomfort in the limbs or back. - Fever: low‑grade temperature elevation. - Injection site reactions: redness, swelling or bruising at the injection site.

Serious or Rare Side Effects: - Splenic rupture: rare but potentially life‑threatening. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty. - Allergic reactions: rash, urticaria, or anaphylaxis.

When using filgrastim, clinicians should observe several precautionary measures to ensure patient safety. - Monitor complete blood count: track neutrophil levels regularly during therapy. - Assess for splenomegaly: evaluate spleen size before and during treatment. - Use caution in patients with active infections: weigh benefits against infection risk. - Adjust dose in renal impairment: consider renal function when dosing. - Avoid use in patients with known hypersensitivity to filgrastim or any excipients. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim can interact with certain medications, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Chemotherapy agents with overlapping myelosuppressive effects: may reduce therapeutic benefit. - Corticosteroids at high doses: can blunt neutrophil response.

Moderate Interactions (Monitor Closely): - Antimicrobial agents (e.g., penicillins): may increase risk of hypersensitivity. - Immunosuppressants (e.g., cyclosporine): may alter neutrophil dynamics. - Vaccines (live attenuated): potential for altered immune response.